Literature DB >> 21704408

Nuclear epidermal growth factor receptor modulates cellular radio-sensitivity by regulation of chromatin access.

Klaus Dittmann1, Claus Mayer, Birgit Fehrenbacher, Martin Schaller, Rainer Kehlbach, H Peter Rodemann.   

Abstract

PURPOSE: Nuclear EGFR is involved in cellular stress management and regulation of cellular radio-sensitivity. The aim of this study was to elucidate the molecular mode of nuclear EGFR action.
METHODS: Radiation induced nuclear EGFR-shuttling and EGFR-foci formation was analyzed with immunohistochemistry and confocal microscopy. Composition of γH(2)AX-protein complexes was analyzed by western-blotting after immuno-precipitation. Functional relevance of nuclear EGFR was analyzed after siRNA mediated depletion of EGFR with respect to activation of ATM, histone H3 acetylation, residual DNA-damage and cell survival after irradiation.
RESULTS: Following radiation nuclear EGFR was localized in foci similar to γH(2)AX. EGFR co-localized in a sub-fraction of γH(2)AX-foci. Analysis of composition of γH(2)AX-complexes revealed presence of EGFR, ATM, promyelocytic leukemia protein (PML), histone H3 and hetero-chromatin binding protein (HP1) in response to radiation. Depletion of EGFR protein inhibited ATM activation due to inhibition of acetylase TIP60 activity following irradiation. Consequently, histone H3 acetylation and phosphorylation was blocked and chromatin could not be opened for repair. Thus, residual DNA-damage was increased 24 h after irradiation and cells were radio-sensitized. Comparable results were obtained when cells were treated with EGFR-NLS-peptide, which blocks EGFR nuclear shuttling specifically.
CONCLUSIONS: Nuclear EGFR is part of DNA-damage repair complex and is involved in regulation of TIP60-acetylase activity. TIP60 is essential for ATM activation and chromatin relaxation which is a prerequisite for DNA-repair in heterochromatic DNA. Thus interventional EGFR strategies during tumor treatment may also interact with DNA-repair by blocking access to damaged DNA.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704408     DOI: 10.1016/j.radonc.2011.06.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  20 in total

Review 1.  [Experimental tumor therapy].

Authors:  M Baumann; D Zips; M Krause
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

2.  EGFR inhibits DNA mismatch repair.

Authors:  Peggy Hsieh; Alexander H Pearlman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 3.  [Molecular signaling pathways. Mechanisms and clinical use].

Authors:  N Cordes; F Rödel; H-P Rodemann
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

4.  Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells.

Authors:  Ayman Oweida; Zeinab Sharifi; Hani Halabi; Yaoxian Xu; Siham Sabri; Bassam Abdulkarim
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742

Review 5.  The nuclear epidermal growth factor receptor signaling network and its role in cancer.

Authors:  Toni M Brand; Mari Iida; Chunrong Li; Deric L Wheeler
Journal:  Discov Med       Date:  2011-11       Impact factor: 2.970

Review 6.  Opportunities and challenges of radiotherapy for treating cancer.

Authors:  Dörthe Schaue; William H McBride
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

7.  Biodistribution, pharmacokinetics and radioimmunotherapy of 188Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice.

Authors:  Ya-Jen Chang; Chung-Li Ho; Kai-Hung Cheng; Wan-I Kuo; Wan-Chi Lee; Keng-Li Lan; Chih-Hsien Chang
Journal:  Invest New Drugs       Date:  2019-01-05       Impact factor: 3.850

8.  Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study.

Authors:  Agata I Rembielak; Pooja Jain; Andrew S Jackson; Melanie M Green; Gillian R Santorelli; Gillian A Whitfield; Adrian Crellin; Angel Garcia-Alonso; Ganesh Radhakrishna; James Cullen; M Ben Taylor; Ric Swindell; Catharine M West; Juan Valle; Azeem Saleem; Patricia M Price
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

9.  Epidermal growth factor receptor targeted nuclear delivery and high-resolution whole cell X-ray imaging of Fe3O4@TiO2 nanoparticles in cancer cells.

Authors:  Ye Yuan; Si Chen; Tatjana Paunesku; Sophie Charlotte Gleber; William C Liu; Caroline B Doty; Rachel Mak; Junjing Deng; Qiaoling Jin; Barry Lai; Keith Brister; Claus Flachenecker; Chris Jacobsen; Stefan Vogt; Gayle E Woloschak
Journal:  ACS Nano       Date:  2013-11-27       Impact factor: 15.881

10.  Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.

Authors:  Toni M Brand; Mari Iida; Emily F Dunn; Neha Luthar; Kellie T Kostopoulos; Kelsey L Corrigan; Matthew J Wleklinski; David Yang; Kari B Wisinski; Ravi Salgia; Deric L Wheeler
Journal:  Mol Cancer Ther       Date:  2014-03-14       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.